Skip to main content

Quest Diagnostics Inc(DGX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading

PR Newswire - Thu Jul 13, 2023

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer

SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with  Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.